US equities |
MU $1,049.63 ▼-1.45% NVDA $229.21 ▲+0.36% SNDK $1,740.06 ▲+0.01% TSLA $357.09 ▲+0.64% INTC $119.72 ▼-0.42% AMD $612.04 ▲+0.05% GOOGL $340.13 ▼-1.15% SPCX $150.62 ▼-0.16%
FinancialContent Watchlist

Articles published by Innate Pharma S.A.

News headline image
Number of Shares and Voting Rights of Innate Pharma as of January 1, 2024
From Innate Pharma S.A.
Via Business Wire
Tickers IPHA
News headline image
Innate Pharma Announces IPH5201 Phase 2 Study in Lung Cancer
From Innate Pharma S.A.
Via Business Wire
Tickers IPHA
News headline image
Outcome of Innate Pharma’s 2022 Annual General Meeting
From Innate Pharma S.A.
Via Business Wire
Tickers IPHA
News headline image
Number of Shares and Voting Rights of Innate Pharma as of January 1, 2022
From Innate Pharma S.A.
Via Business Wire
Tickers IPHA
News headline image
Innate Pharma: Monalizumab Combined With Cetuximab and Durvalumab Demonstrates Anti-Tumor Activity in First-Line Recurrent or Metastatic Head and Neck Cancer at ESMO Immuno-Oncology 2021 Congress
From Innate Pharma S.A.
Via Business Wire
Tickers IPHA
News headline image
Innate Pharma Third Quarter 2021 Report
From Innate Pharma S.A.
Via Business Wire
Tickers IPHA